Development  ||| S:0 E:12 ||| NN
of  ||| S:12 E:15 ||| IN
a  ||| S:15 E:17 ||| DT
plasma-  ||| S:17 E:25 ||| JJ
and  ||| S:25 E:29 ||| CC
albumin-free  ||| S:29 E:42 ||| JJ
recombinant  ||| S:42 E:54 ||| JJ
von  ||| S:54 E:58 ||| NNP
Willebrand  ||| S:58 E:69 ||| NNP
factor  ||| S:69 E:76 ||| NN
Baxter  ||| S:76 E:83 ||| NNP
has  ||| S:83 E:87 ||| VBZ
developed  ||| S:87 E:97 ||| VBN
a  ||| S:97 E:99 ||| DT
recombinant  ||| S:99 E:111 ||| JJ
therapy  ||| S:111 E:119 ||| NN
for  ||| S:119 E:123 ||| IN
treating  ||| S:123 E:132 ||| VBG
von  ||| S:132 E:136 ||| NNP
Willebrand ||| S:136 E:146 ||| NNP
's  ||| S:146 E:149 ||| POS
disease ||| S:149 E:156 ||| NN
.  ||| S:156 E:158 ||| .
Recombinant  ||| S:158 E:170 ||| NNP
VWF  ||| S:170 E:174 ||| NNP
is  ||| S:174 E:177 ||| VBZ
co-expressed  ||| S:177 E:190 ||| JJ
with  ||| S:190 E:195 ||| IN
the  ||| S:195 E:199 ||| DT
rFVIII  ||| S:199 E:206 ||| JJ
in  ||| S:206 E:209 ||| IN
CHO  ||| S:209 E:213 ||| NNP
cells  ||| S:213 E:219 ||| NNS
used  ||| S:219 E:224 ||| VBN
to  ||| S:224 E:227 ||| TO
produce  ||| S:227 E:235 ||| VB
the  ||| S:235 E:239 ||| DT
rFVIII  ||| S:239 E:246 ||| JJ
product  ||| S:246 E:254 ||| NN
Advate ||| S:254 E:260 ||| NNP
.  ||| S:260 E:262 ||| .
This  ||| S:262 E:267 ||| DT
rVWF  ||| S:267 E:272 ||| NN
is  ||| S:272 E:275 ||| VBZ
used  ||| S:275 E:280 ||| VBN
as  ||| S:280 E:283 ||| IN
a  ||| S:283 E:285 ||| DT
drug  ||| S:285 E:290 ||| NN
component  ||| S:290 E:300 ||| NN
for  ||| S:300 E:304 ||| IN
a  ||| S:304 E:306 ||| DT
rVWF-rFVIII  ||| S:306 E:318 ||| JJ
complex  ||| S:318 E:326 ||| JJ
drug  ||| S:326 E:331 ||| NN
product ||| S:331 E:338 ||| NN
.  ||| S:338 E:340 ||| .
CHO  ||| S:340 E:344 ||| NNP
cells  ||| S:344 E:350 ||| NNS
produce  ||| S:350 E:358 ||| VBP
partially  ||| S:358 E:368 ||| RB
processed  ||| S:368 E:378 ||| VBN
and  ||| S:378 E:382 ||| CC
partially  ||| S:382 E:392 ||| RB
un-processed  ||| S:392 E:405 ||| JJ
rVWF  ||| S:405 E:410 ||| NN
still  ||| S:410 E:416 ||| RB
containing  ||| S:416 E:427 ||| VBG
the  ||| S:427 E:431 ||| DT
pro-peptide ||| S:431 E:442 ||| JJ
.  ||| S:442 E:444 ||| .
In  ||| S:444 E:447 ||| IN
order  ||| S:447 E:453 ||| NN
to  ||| S:453 E:456 ||| TO
make  ||| S:456 E:461 ||| VB
a  ||| S:461 E:463 ||| DT
consistent  ||| S:463 E:474 ||| JJ
preparation  ||| S:474 E:486 ||| NN
containing  ||| S:486 E:497 ||| VBG
mature  ||| S:497 E:504 ||| JJ
and  ||| S:504 E:508 ||| CC
processed  ||| S:508 E:518 ||| VBN
rVWF  ||| S:518 E:523 ||| JJ
only  ||| S:523 E:528 ||| JJ
rVWF  ||| S:528 E:533 ||| NN
is  ||| S:533 E:536 ||| VBZ
exposed  ||| S:536 E:544 ||| VBN
to  ||| S:544 E:547 ||| TO
recombinant  ||| S:547 E:559 ||| VB
furin  ||| S:559 E:565 ||| VBN
to  ||| S:565 E:568 ||| TO
remove  ||| S:568 E:575 ||| VB
the  ||| S:575 E:579 ||| DT
pro-peptide ||| S:579 E:590 ||| JJ
.  ||| S:590 E:592 ||| .
Recombinant  ||| S:592 E:604 ||| NNP
VWF  ||| S:604 E:608 ||| NNP
and  ||| S:608 E:612 ||| CC
furin  ||| S:612 E:618 ||| NNS
are  ||| S:618 E:622 ||| VBP
produced  ||| S:622 E:631 ||| VBN
under  ||| S:631 E:637 ||| IN
serum-  ||| S:637 E:644 ||| JJ
and  ||| S:644 E:648 ||| CC
protein-free  ||| S:648 E:661 ||| JJ
conditions ||| S:661 E:671 ||| NNS
.  ||| S:671 E:673 ||| .
It  ||| S:673 E:676 ||| PRP
is  ||| S:676 E:679 ||| VBZ
highly  ||| S:679 E:686 ||| RB
purified  ||| S:686 E:695 ||| VBN
by  ||| S:695 E:698 ||| IN
a  ||| S:698 E:700 ||| DT
series  ||| S:700 E:707 ||| NN
of  ||| S:707 E:710 ||| IN
chromatographic  ||| S:710 E:726 ||| JJ
steps  ||| S:726 E:732 ||| NNS
and  ||| S:732 E:736 ||| CC
formulated  ||| S:736 E:747 ||| VBN
in  ||| S:747 E:750 ||| IN
a  ||| S:750 E:752 ||| DT
protein-free  ||| S:752 E:765 ||| JJ
buffer  ||| S:765 E:772 ||| NN
and  ||| S:772 E:776 ||| CC
has  ||| S:776 E:780 ||| VBZ
a  ||| S:780 E:782 ||| DT
homogeneous  ||| S:782 E:794 ||| JJ
multimer  ||| S:794 E:803 ||| JJ
distribution ||| S:803 E:815 ||| NN
.  ||| S:815 E:817 ||| .
The  ||| S:817 E:821 ||| DT
specific  ||| S:821 E:830 ||| JJ
activity  ||| S:830 E:839 ||| NN
is  ||| S:839 E:842 ||| VBZ
higher  ||| S:842 E:849 ||| JJR
in  ||| S:849 E:852 ||| IN
rVWF  ||| S:852 E:857 ||| JJ
than  ||| S:857 E:862 ||| IN
in  ||| S:862 E:865 ||| IN
commercial  ||| S:865 E:876 ||| JJ
plasma-derived  ||| S:876 E:891 ||| JJ
VWF-FVIII  ||| S:891 E:901 ||| JJ
complex  ||| S:901 E:909 ||| JJ
products ||| S:909 E:917 ||| NNS
.  ||| S:917 E:919 ||| .
SDS  ||| S:919 E:923 ||| NNP
agarose  ||| S:923 E:931 ||| VBD
electrophoretic  ||| S:931 E:947 ||| JJ
analysis  ||| S:947 E:956 ||| NN
shows  ||| S:956 E:962 ||| VBZ
the  ||| S:962 E:966 ||| DT
presence  ||| S:966 E:975 ||| NN
of  ||| S:975 E:978 ||| IN
ultra-high  ||| S:978 E:989 ||| JJ
molecular  ||| S:989 E:999 ||| JJ
weight  ||| S:999 E:1006 ||| NN
multimers ||| S:1006 E:1015 ||| NN
.  ||| S:1015 E:1017 ||| .
The  ||| S:1017 E:1021 ||| DT
FVIII-binding  ||| S:1021 E:1035 ||| JJ
capacity  ||| S:1035 E:1044 ||| NN
and  ||| S:1044 E:1048 ||| CC
affinity  ||| S:1048 E:1057 ||| NN
of  ||| S:1057 E:1060 ||| IN
rVWF  ||| S:1060 E:1065 ||| JJ
to  ||| S:1065 E:1068 ||| TO
FVIII  ||| S:1068 E:1074 ||| NNP
is  ||| S:1074 E:1077 ||| VBZ
comparable  ||| S:1077 E:1088 ||| JJ
to  ||| S:1088 E:1091 ||| TO
VWF  ||| S:1091 E:1095 ||| NNP
in  ||| S:1095 E:1098 ||| IN
plasma ||| S:1098 E:1104 ||| NN
.  ||| S:1104 E:1106 ||| .
Carbohydrate  ||| S:1106 E:1119 ||| JJ
analysis  ||| S:1119 E:1128 ||| NN
shows  ||| S:1128 E:1134 ||| VBZ
an  ||| S:1134 E:1137 ||| DT
intact  ||| S:1137 E:1144 ||| JJ
glycosylation  ||| S:1144 E:1158 ||| JJ
pattern ||| S:1158 E:1165 ||| NN
.  ||| S:1165 E:1167 ||| .
Recombinant  ||| S:1167 E:1179 ||| NNP
VWF  ||| S:1179 E:1183 ||| NNP
binds  ||| S:1183 E:1189 ||| VBD
to  ||| S:1189 E:1192 ||| TO
collagen  ||| S:1192 E:1201 ||| VB
and  ||| S:1201 E:1205 ||| CC
promotes  ||| S:1205 E:1214 ||| VBZ
platelet  ||| S:1214 E:1223 ||| JJ
adhesion  ||| S:1223 E:1232 ||| NN
under  ||| S:1232 E:1238 ||| IN
shear  ||| S:1238 E:1244 ||| JJ
stress ||| S:1244 E:1250 ||| NN
.  ||| S:1250 E:1252 ||| .
It  ||| S:1252 E:1255 ||| PRP
stabilizes  ||| S:1255 E:1266 ||| VBZ
endogenous  ||| S:1266 E:1277 ||| JJ
FVIII  ||| S:1277 E:1283 ||| NN
in  ||| S:1283 E:1286 ||| IN
VWF-deficient  ||| S:1286 E:1300 ||| JJ
knock-out  ||| S:1300 E:1310 ||| JJ
mice  ||| S:1310 E:1315 ||| NNS
as  ||| S:1315 E:1318 ||| RB
seen  ||| S:1318 E:1323 ||| VBN
by  ||| S:1323 E:1326 ||| IN
a  ||| S:1326 E:1328 ||| DT
secondary  ||| S:1328 E:1338 ||| JJ
rise  ||| S:1338 E:1343 ||| NN
in  ||| S:1343 E:1346 ||| IN
murine  ||| S:1346 E:1353 ||| JJ
FVIII ||| S:1353 E:1358 ||| NNP
.  ||| S:1358 E:1360 ||| .
